Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Serina Therapeutics, Inc.SER · Entity 9581 | Director | June 17, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Serina Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2036-06-17 | Direct | 15,250 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 15,250 · Balance 15,250 F1: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 22, 2026 23:12 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 15,250 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0002016188-26-000004 · wk-form4_1782169969.xml · derivative · entry 1 Marshall Richard Peter · CIK 0002016188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2036-06-17 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| May 19, 2026 Filed May 22, 2026 20:59 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 12,183 | $1.65 | $20,101.95 |
DisclosureSEC source: 0002016188-26-000002 · wk-form4_1779483581.xml · nonDerivative · entry 1 Marshall Richard Peter · CIK 0002016188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,183 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.59 per share to a high purchase price of $1.73 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 01:02 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0002016188-25-000003 · wk-form4_1762822939.xml · derivative · entry 1 Marshall Richard Peter · CIK 0002016188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-11-07 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:58 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $11.83 | $0.00 |
DisclosureSEC source: 0001493152-24-013085 · ownership.xml · derivative · entry 1 Marshall Richard Peter · CIK 0002016188 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-04-01 F1 · derivative.exercise_date: The stock options vest in three equal installments on April 1, 2025, April 1, 2026 and April 1, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.